EDITORIAL
1654 Teneligliptin: A potential therapeutic approach for diabetic cardiomyopathy
   Al Madhoun A

1659 Diabetic cardiomyopathy: Importance of direct evidence to support the roles of NOD-like receptor protein 3 inflammasome and pyroptosis
   Cai L, Tan Y, Islam MS, Horowitz M, Wintergerst KA

1663 Diabetes and susceptibility to COVID-19: Risk factors and preventive and therapeutic strategies

1672 Periodontal disease: A silent factor in the development and progression of diabetic retinopathy
   Lomelí Martínez SM, Cortés Trujillo I, Martínez Nieto M, Mercado González AE

1677 Diabetic cardiomyopathy: Emerging therapeutic options
   Fernandez CJ, Shetty S, Pappachan JM

1683 Urgent call for attention to diabetes-associated hospital infections
   Yu XL, Zhou LY, Huang X, Li XY, Pan QQ, Wang MK, Yang JS

REVIEW
1692 Bariatric surgery and diabetes: Current challenges and perspectives
   He YF, Hu XD, Liu JQ, Li HM, Lu SF

MINIREVIEWS
1704 Mechanism underlying the effects of exercise against type 2 diabetes: A review on research progress
   Peng CJ, Chen S, Yan SY, Zhao JN, Luo ZW, Qian Y, Zhao GL

1712 Advances in the treatment of diabetic peripheral neuropathy by modulating gut microbiota with traditional Chinese medicine
   Li YY, Guan RQ, Hong ZB, Wang YL, Pan LM

ORIGINAL ARTICLE
Case Control Study
1717 Autoantibodies against beta cells to predict early insulin requirements in pediatric patients with clinically diagnosed type 2 diabetes
   Molina JM, Medina PG, Gomez RA, Herrera JR, Martínez NL, Hernández B, García Y
Contents

World Journal of Diabetes

Monthly Volume 15 Number 8 August 15, 2024

Retrospective Study
1726 Clinically significant changes in anal sphincter hiatal area in patients with gestational diabetes mellitus and pelvic organ prolapse
Wang QH, Liu LH, Ying H, Chen MX, Zhou CJ, Li H

Randomized Controlled Trial
1734 Efficacy comparison of multipoint and single point scanning panretinal laser photocoagulation in non-proliferative diabetic retinopathy treatment
Zhang YZ, Gong H, Yang J, Bu JP, Yang HL

Clinical and Translational Research
1742 Association between composite dietary antioxidant index and stroke among individuals with diabetes

Basic Study
1753 Functional analysis of the novel mitochondrial tRNA\textsuperscript{Trp} and tRNA\textsuperscript{Ser(AGY)} variants associated with type 2 diabetes mellitus
Ding Y, Yu XJ, Guo QX, Leng JH

1764 Intestinal glucagon-like peptide-1: A new player associated with impaired counterregulatory responses to hypoglycaemia in type 1 diabetic mice
Jin FX, Wang Y, Li MN, Li RJ, Guo JT

1778 Mitigating diabetes-related complications: Empowering metformin with cholecalciferol and taurine supplementation in type 2 diabetic rats
Attia MS, Ayman F, Attia MS, Yahya G, Zahra MH, Khalil MMI, Diab AAA

SYSTEMATIC REVIEWS
1793 Safety of teplizumab in patients with high-risk for diabetes mellitus type 1: A systematic review

META-ANALYSIS
1802 Circulating glycated albumin levels and gestational diabetes mellitus
Xiong W, Zeng ZH, Xu Y, Li H, Lin H

CASE REPORT
1811 Transient diabetes mellitus with ABCC8 variant successfully treated with sulfonylurea: Two case reports and review of literature
Shen LH, Cui Y, Fu DX, Yang W, Wu SN, Wang HZ, Yang IH, Chen YX, Wei HY
LETTER TO THE EDITOR

1820 Enhancing diabetic retinopathy screening: Non-mydriatic fundus photography-assisted telemedicine for improved clinical management
Szulborski KJ, Ramsey DJ

1824 Vitamin D and selenium for type 2 diabetes mellitus with Hashimoto’s thyroiditis: Dosage and duration insights
Yu YF, Shangguan XL, Tan DN, Qin LN, Yu R
ABOUT COVER
Peer Review of World Journal of Diabetes, Mustafa Arslan, MD, Professor, Department of Anesthesiology and Reanimation, School of Medicine, Yenimahalle 48, Sok Seda Apt 24-17, Ankara 06500, Türkiye. mustarslan@gmail.com

AIMS AND SCOPE
The primary aim of World Journal of Diabetes (WJD, World J Diabetes) is to provide scholars and readers from various fields of diabetes with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJD mainly publishes articles reporting research results and findings obtained in the field of diabetes and covering a wide range of topics including risk factors for diabetes, diabetes complications, experimental diabetes mellitus, type 1 diabetes mellitus, type 2 diabetes mellitus, gestational diabetes, diabetic angiopathies, diabetic cardiomyopathies, diabetic coma, diabetic ketoacidosis, diabetic nephropathies, diabetic neuropathies, Donohue syndrome, fetal macrosomia, and prediabetic state.

INDEXING/ABSTRACTING
The WJD is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as ScSearch®), Current Contents/Clinical Medicine, Journal Citation Reports/Science Edition, PubMed, PubMed Central, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2024 Edition of Journal Citation Reports® cites the 2023 journal impact factor (JIF) for WJD as 4.2; JIF without journal self cites: 4.1; 5-year JIF: 4.2; JIF Rank: 40/186 in endocrinology and metabolism; JIF Quartile: Q1; and 5-year JIF Quartile: Q2.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Yu-Xi Chen; Production Department Director: Xu Guo; Cover Editor: Jia-Ru Fan.

NAME OF JOURNAL
World Journal of Diabetes

ISSN
ISSN 1948-9358 (online)

LAUNCH DATE
June 15, 2010

FREQUENCY
Monthly

EDITORS-IN-CHIEF
Lu Cai, Md. Shahidul Islam, Michael Horowitz

EDITORIAL BOARD MEMBERS

PUBLICATION DATE
August 15, 2024

COPYRIGHT
© 2024 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS
https://www.wjgnet.com/bpg/gerinfo/204

GUIDELINES FOR ETHICS DOCUMENTS
https://www.wjgnet.com/bpg/gerinfo/287

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
https://www.wjgnet.com/bpg/gerinfo/240

PUBLICATION ETHICS
https://www.wjgnet.com/bpg/gerinfo/288

PUBLICATION MISCONDUCT
https://www.wjgnet.com/bpg/gerinfo/208

ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/bpg/gerinfo/242

STEPS FOR SUBMITTING MANUSCRIPTS
https://www.wjgnet.com/bpg/gerinfo/239

ONLINE SUBMISSION
https://www.f6publishing.com
Vitamin D and selenium for type 2 diabetes mellitus with Hashimoto’s thyroiditis: Dosage and duration insights

Yun-Feng Yu, Xue-Li Shangguan, Dan-Ni Tan, Li-Na Qin, Rong Yu

Abstract
This letter discusses the publication by Feng et al. Iodine, selenium, and vitamin D are closely associated with thyroid hormone production in humans; however, the efficacy of selenium and vitamin D supplementation for type 2 diabetes mellitus (T2DM) patients with Hashimoto’s thyroiditis (HT) remains controversial. In the retrospective study we discuss herein, the authors highlighted significant improvements in thyroid function, thyroid antibodies, blood glucose, and blood lipid in T2DM patients with HT following addition of vitamin D and selenium to their antidiabetic regimens, underscoring the value of these supplements. Our team is currently engaged in research exploring the relationship between micronutrients and HT, and we have obtained invaluable insights from the aforementioned study. Based on this research and current literature, we recommend a regimen of 4000 IU/day of vitamin D and 100-200 μg/day of selenium for over three months to six months for patients with HT, particularly for those with concurrent T2DM.

Key Words: Vitamin D; Selenium; Type 2 diabetes mellitus; Hashimoto’s thyroiditis; Dosage; Duration
Core Tip: Supplementation with vitamin D and selenium shows promise in improving the prognosis of type 2 diabetes mellitus (T2DM) and Hashimoto's thyroiditis (HT). Despite controversies surrounding their efficacy, a retrospective study discussed in this letter reveals significant benefits from adding these supplements to antidiabetic regimens. Based on this research and current literature, we recommend a regimen of 4000 IU/day of vitamin D and 100-200 μg/day of selenium for over three to six months for patients with HT, particularly for those with concurrent T2DM.

Citation: Yu YF, Shangguan XL, Tan DN, Qin LN, Yu R. Vitamin D and selenium for type 2 diabetes mellitus with Hashimoto’s thyroiditis: Dosage and duration insights. World J Diabetes 2024; 15(8): 1824-1828
DOI: https://dx.doi.org/10.4239/wjd.v15.i8.1824

TO THE EDITOR

We are fortunate to have read the article, which was written by Feng et al[1] and published in the World Journal of Diabetes. We extend our felicitations to the authors for completing the aforementioned retrospective study and providing new insights into treating type 2 diabetes mellitus (T2DM) patients with Hashimoto’s thyroiditis (HT). The study by Feng et al [1] revealed that, compared with antidiabetic drugs alone, the supplementation of 4000 IU vitamin D and 200 μg selenium daily for three to six months, in combination with standard antidiabetic drugs, significantly improved thyroid function, thyroid antibodies, blood glucose, and blood lipid in T2DM patients with HT. In this letter, therefore, we discuss the ideal dosage and duration of vitamin D and selenium administration in treatment of HT, taking into account the study by Feng et al[1] as well as previous literature.

DOSE AND DURATION OF VITAMIN D

The optimal dosage and duration of vitamin D supplementation in HT patients is controversial. An early randomized controlled trial from Türkiye revealed that vitamin D supplementation of 1000 IU per day for one month significantly reduced thyroid peroxidase antibodies (TPOAb) and thyroglobulin antibodies (TGAb) in patients with autoimmune thyroid disease[2]. A prospective study from Greece indicated that vitamin D supplementation of 1200-4000 IU per day for four months significantly reduced TPOAb in HT patients, although they observed no significant effects on TGAb or thyroid-stimulating hormone (TSH)[3]. Additionally, a study from Iran found that a vitamin D supplementation of 50000 IU per week for three months significantly reduced TGAbs and TSH levels in female patients, compared to those who received a placebo, with no significant effect on TPOAb[4]. Although these studies reported different results on the benefits of vitamin D supplementation, they are all in concordance that vitamin D supplementation is beneficial for HT patients. Taken in combination, the results of these studies suggest that an average daily vitamin D supplementation ranging from 1000 to 7143 IU is effective for treating HT. Of note, the study by Feng et al[1] demonstrated that, in addition to thyroid function and thyroid antibodies, 4000 IU of vitamin D per day improved blood glucose and lipid levels in T2DM patients with HT, suggesting that high-dosage vitamin D may have the additional benefit of modulating glucose and lipid metabolism in such patients. In light of this additional evidence, therefore, we recommend supplementation with 4000 IU of vitamin D daily for HT patients, particularly those HT patients with T2DM.

With regard to the appropriate duration of vitamin D supplementation, a clinical study from Turkey discovered that a one-month duration allowed for reduction of TPOAb and TGAb levels in patients with autoimmune thyroid disease[2], which is the lowest effective duration reported to date. A subsequent meta-analysis indicated that vitamin D supplementation for more than three months reduced TPOAb and TGAb levels in HT patients, whereas treatment for three months or less reduced only TGAb levels[5]. A recent meta-analysis further indicated that vitamin D supplementation for longer than three months not only reduced TPOAb and TGAb, but also increased free triiodothyronine (FT3) and free thyroxine (FT4) in HT patients[5]. In contrast, treatments lasting three months only resulted in a reduction of TGAb[6]. These findings, therefore, demonstrate that vitamin D supplementation for longer than three months provided additional benefits for HT patients. Of note, the study by Feng et al[1] revealed that vitamin D supplementation for six months was more effective in improving FT3, FT4, TSH, TPOAb, and TGAb in T2DM patients with HT compared with a three-month regimen. With regard to treatment duration, therefore, we recommend that HT patients take vitamin D for 3-6 months or more.

DOSE AND DURATION OF SELENIUM

As with vitamin D, the optimal dosage and duration of selenium supplementation in the treatment for HT remain unclear. With regard to dosage, a recent meta-analysis of 35 studies revealed that a daily selenium supplementation of 100 μg or more reduced TSH and TPOAb in HT patients[7]. Unfortunately, it did not compare the benefits of various selenium dosages. In fact, most previous clinical studies set the daily intake of selenium at 200 μg, regardless of the
selenium type, emphasizing that 200 μg/day of selenium improved the prognoses of HT patients.[8,9] Similarly, the study by Feng et al.[1] demonstrated that a daily supplementation of 200 μg selenium, in addition to the standard antidiabetic drugs and vitamin D, effectively improved thyroid function and antibodies in T2DM patients with HT. However, a high dosage of selenium may be associated with potential adverse events. It has been reported that selenium dosages exceeding 400 μg/day can lead to acute toxic symptoms in the gastrointestinal and nervous systems,[10], and supplementation of 200 μg/day selenium may increase the risk of developing T2DM.[11]. Therefore, we recommend that the daily selenium supplementation for HT patients be maintained between 100 and 200 μg.

With regard to the duration of selenium treatment, an early meta-analysis indicated that a three-month duration of selenium supplementation significantly reduced TPOAb and TGAb levels in patients with autoimmune thyroiditis, while supplementation for six or twelve months did not have a significant effect on TPOAb or TGAb.[12]. Subsequently, another meta-analysis found that selenium supplementation led to reduced levels of TPOAb and TGAb after three months, while only TGAb was reduced after six months, and no reduction in thyroid antibodies was seen after twelve months.[13]. In contrast, Feng et al.[1] demonstrated that selenium supplementation for both three and six months reduced TPOAb and TGAb levels. We speculate that this difference may be attributable to the synergistic effect of supplemental selenium and vitamin D in HT patients, as the selenium supplementation by Feng et al.[1] was based on concurrent vitamin D supplementation. As it has been shown that selenium treatment for three or six months is beneficial, despite concerns about its long-term effects, we recommend that the duration of selenium supplementation should be set at 3-6 months. In summary, combined with research by Feng et al.[1] and the current literature, we recommend a regimen of 4000 IU/day of vitamin D and 100-200 μg/day of selenium for over three months to six months for patients with HT, particularly for those with concurrent T2DM.

SYNERGISTIC EFFECT OF VITAMIN D AND SELENIUM

In addition to the optimal dosage and duration, the existence of synergy between vitamin D and selenium remains unclear, as does its mechanism. Evidence suggests that selenium enhances the effects of vitamin D in the treatment of HT. Krysiak et al.[14] included 47 female patients with HT who had normal thyroid function and vitamin D deficiency. Of these, 23 had been treated with selenomethionine for 12 months prior to treatment, while the other 24 had not received selenium treatment. After six months of vitamin D treatment, the levels of TPOAb and TGAb in patients with HT significantly decreased, and these changes were more pronounced in patients who had received selenomethionine.[14]. This indicates that selenium supplementation may enhance the therapeutic effects of vitamin D on HT. Although a nutritional study indicated that vitamin D promotes selenium absorption, it is unclear whether vitamin D enhances the efficacy of selenium in the treatment of HT.[15]. In summary, there may be a synergistic effect between vitamin D and selenium; however, its strength and formation mechanisms require further exploration.

LIMITATIONS AND PROSPECTS

Although the study by Feng et al.[1] provided clinical evidence for a supplementation regimen of vitamin D combined with selenium in the treatment of T2DM with HT, it did have some limitations. First, it was a retrospective case-control study with a lack of randomization and blinding of patients, leading to potential selection and implementation biases. Second, as there was no treatment group with selenium-only supplementation, it is unclear whether selenium and vitamin D play a synergistic role in the treatment of T2DM with HT. Third, it is unclear whether the long-term effects of vitamin D combined with selenium are observed in the treatment of T2DM with HT, as the study by Feng et al.[1] only assessed these effects at three- and six-month timepoints. Considering these limitations, it is too early to conclude that a combination of vitamin D and selenium has a significant clinical effect in the treatment of T2DM with HT. In the future, multicenter, randomized controlled, double-blind clinical trials should be conducted to further evaluate the short- and long-term effects of vitamin D alone, selenium alone, and a combination of vitamin D and selenium in the treatment of T2DM with HT.

Finally, we wish to express our appreciation to Feng et al.[1] for sharing their research and novel findings addressing the clinical effects of vitamin D and selenium in specific HT patients. In addition to increasing confidence in our practice, the aforementioned study provides new insights and evidence for clinicians to gain a deeper understanding of the combination of vitamin D and selenium, ultimately enriching our treatment of T2DM with HT.

CONCLUSION

In conclusion, this study highlights the potential benefits of vitamin D and selenium supplementation in improving thyroid function, reducing thyroid antibody levels, and optimizing blood glucose and lipid levels in patients with T2DM and HT. Based on current research, we recommend a daily regimen of 4000 IU of vitamin D and 100-200 μg of selenium for three to six months. Although our findings are promising, they require validation in larger, randomized controlled trials to confirm their efficacy and safety. Future research should focus on the potential synergistic effects of these supplements and elucidate their long-term effects in patients with concurrent T2DM and HT.
REFERENCES


